Discovering a potent small molecule inhibitor for gankyrin using de novo drug design approach

Gankyrin is an oncoprotein composed of six ankyrin repeats, over-expressed in the Hepatocellular Carcinoma (HCC), and directly involved in the cell cycle regulation. Therefore, it is a potential drug target to restrict the growth of cancer cell and activation of apoptosis. We have successfully designed a potent ligand to inhibit the activity of gankyrin. Using docking approach we designed a potential ligand, which is exactly fitting in the cavity of gankyrin and forming many close interactions to protein atoms including its active site residues. This molecule shows minimum energy and good binding affinity for gankyrin.

[1]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[2]  L. Lai,et al.  Calculating partition coefficient by atom-additive method , 2000 .

[3]  David W Ritchie,et al.  Docking essential dynamics eigenstructures , 2005, Proteins.

[4]  M. Horikoshi,et al.  Crystal Structure of the Homolog of the Oncoprotein Gankyrin, an Interactor of Rb and CDK4/6* , 2004, Journal of Biological Chemistry.

[5]  Zhenjiang Li,et al.  Personal Experience with Four Kinds of Chemical Structure Drawing Software: Review on ChemDraw, ChemWindow, ISIS/Draw, and ChemSketch , 2004, J. Chem. Inf. Model..

[6]  Jie-Oh Lee,et al.  Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7 , 1998, Nature.

[7]  M. Tsai,et al.  Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16. , 2007, Journal of molecular biology.

[8]  Matthew L. Danielson,et al.  Computer-aided drug design platform using PyMOL , 2011, J. Comput. Aided Mol. Des..

[9]  Tomoko Masuda,et al.  The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. , 2005, Cancer cell.

[10]  S. Tsunoda,et al.  Gankyrin oncoprotein overexpression as a critical factor for tumor growth in human esophageal squamous cell carcinoma and its clinical significance , 2008, International journal of cancer.

[11]  Chris Morley,et al.  Pybel: a Python wrapper for the OpenBabel cheminformatics toolkit , 2008, Chemistry Central journal.

[12]  Yoshihide Hayashizaki,et al.  Structure of the oncoprotein gankyrin in complex with S6 ATPase of the 26S proteasome. , 2007, Structure.

[13]  H. Marusawa,et al.  Role of a novel oncogenic protein, gankyrin, in hepatocyte proliferation , 2003, Journal of Gastroenterology.

[14]  Katsuhiko Itoh,et al.  Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas , 2000, Nature Medicine.

[15]  Hong-Yang Wang,et al.  Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. , 2002, World journal of gastroenterology.

[16]  M. Tsai,et al.  Solution structure of the human oncogenic protein gankyrin containing seven ankyrin repeats and analysis of its structure--function relationship. , 2004, Biochemistry.

[17]  A. Cheng,et al.  1027 Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of signal transducers and activators of transcription 3 , 2009 .

[18]  M. Schroeder,et al.  LIGSITEcsc: predicting ligand binding sites using the Connolly surface and degree of conservation , 2006, BMC Structural Biology.

[19]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[20]  S. Krzywda,et al.  Crystallization of gankyrin, an oncoprotein that interacts with CDK4 and the S6b (rpt3) ATPase of the 19S regulator of the 26S proteasome. , 2003, Acta crystallographica. Section D, Biological crystallography.

[21]  M. Swindells,et al.  Protein clefts in molecular recognition and function. , 1996, Protein science : a publication of the Protein Society.

[22]  M. Tsai,et al.  Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb. , 2002, Biochemistry.

[23]  C. Rauch.  Toward a mechanical control of drug delivery. On the relationship between Lipinski’s 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data , 2009, European Biophysics Journal.

[24]  G. Lozano,et al.  Gankyrin: an intriguing name for a novel regulator of p53 and RB. , 2005, Cancer cell.

[25]  M. Anzola.  Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis , 2004, Journal of Viral Hepatitis.

[26]  B. Bai,et al.  Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells. , 2010, The Journal of clinical investigation.

[27]  Luhua Lai,et al.  LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design , 2000 .

[28]  Shaomeng Wang,et al.  An Extensive Test of 14 Scoring Functions Using the PDBbind Refined Set of 800 Protein-Ligand Complexes , 2004, J. Chem. Inf. Model..

[29]  R. Baker,et al.  Gankyrin Is an Ankyrin-repeat Oncoprotein That Interacts with CDK4 Kinase and the S6 ATPase of the 26 S Proteasome* , 2002, The Journal of Biological Chemistry.

[30]  Kuen-Feng Chen,et al.  Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3 , 2010, Clinical Cancer Research.

[31]  S. Krzywda,et al.  The Crystal Structure of Gankyrin, an Oncoprotein Found in Complexes with Cyclin-dependent Kinase 4, a 19 S Proteasomal ATPase Regulator, and the Tumor Suppressors Rb and p53* , 2004, Journal of Biological Chemistry.

[32]  R. Mayer,et al.  Gankyrin, the 26 S proteasome, the cell cycle and cancer. , 2006, Biochemical Society transactions.

[33]  David S Goodsell,et al.  Computational docking of biomolecular complexes with AutoDock. , 2009, Cold Spring Harbor protocols.

[34]  Konrad Büssow,et al.  X‐ray structure of human gankyrin, the product of a gene linked to hepatocellular carcinoma , 2004, Proteins.

[35]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.